In Brief

Markwins finishes acquiring Physicians Formula; L’Oreal opens its second hair-color plant in Mexico. More news in brief.

City of Industry, Calif.-based Markwins has acquired all outstanding securities of Physicians Formula Holdings for $75 million, or $4.90 per share in cash, representing a premium of approximately 33% to Physicians Formula's closing stock price on Aug. 14, the firms report Dec. 12. Physicians Formula shareholders also received a special $0.035 per share dividend as part of the transaction. The addition of Physicians Formula represents “a major step towards Markwins' strategy to add an up-market brand in the masstige cosmetics space to its existing dominant entry-point wet n wild brand, and become the next major global innovator of beauty products,” Markwins says, noting the deal also allows the firm to “broaden its scope and service” to more beauty customers around the world. Physicians Formula Chairwoman and CEO Ingrid Jackel will become a Markwins executive and continue to oversee Physicians Formula. The two firms announced the acquisition in September, which required Physicians Formula to back out of a deal with Swander Pace Capital for $10 million less Also see "Physicians Formula Goes To Wet N Wild Owner Markwins For $75 Mil." - HBW Insight, 1 October, 2012..

French beauty giant L'Oreal SA has invested more than $100 million in its second Mexican production plant, expected to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Latin America

Bayer Consumer Health Expands North America And LATAM Supply Capacity

Bayer is investing $52m in its Lerma, Mexico manufacturing site, which the firm said will enable it to increase production of key OTC brands like Aspirin and Alka-Seltzer from 100m to 140m units by 2030.

Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

 

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results

 

Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.

Herbalife's Rising Digital Platform Floats All Boats Other Than Marketing To GLP-1 Patients

 

Direct seller reports Q1 sales up 1% to $1.3bn but net sales off 17.1% from year-ago period to $24.3m. Its distributor ranks jumped so far in 2024, particularly in China, where changes were made in the past year including new company leadership.

More from Geography

AESGP Annual Meeting: Wastewater Directive Impact Assessment ‘Fundamentally Flawed’

 
• By 

AESGP president Jonathan Workman opens the 61st Annual Meeting with calls for industry unity in the face of the problematic revised EU Urban Wastewater Treatment Directive.

Over The Counter: Driving Innovation In France’s Self-Care Market, With NèreS’ Luc Besançon

 
• By 

HBW Insight speaks to NèreS' executive director Luc Besançon about the key issues facing France's self-care industry, especially Rx-to-OTC switch and the revised Urban Wastewater Treatment Directive.

‘We Must Have The Truth’ – Calls For UWWTD Review Intensify As Evidence Looks ‘Shaky’

 
• By 

The evidence underpinning the “polluter pays” principle of the revised Urban Wastewater Treatment Directive - which calls on Europe's pharmaceutical industry to cough up at least 80% of the cost of updating wastewater treatment facilities - is looking increasingly shaky, according to a new report.